Historical Valuation
Sangamo Therapeutics Inc (SGMO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.41 is considered Undervalued compared with the five-year average of -4.15. The fair price of Sangamo Therapeutics Inc (SGMO) is between 1.88 to 4.29 according to relative valuation methord. Compared to the current price of 0.45 USD , Sangamo Therapeutics Inc is Undervalued By 76.02%.
Relative Value
Fair Zone
1.88-4.29
Current Price：0.45
76.02%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Sangamo Therapeutics Inc (SGMO) has a current Price-to-Book (P/B) ratio of 22.62. Compared to its 3-year average P/B ratio of 7.38 , the current P/B ratio is approximately 206.67% higher. Relative to its 5-year average P/B ratio of 5.50, the current P/B ratio is about 311.23% higher. Sangamo Therapeutics Inc (SGMO) has a Forward Free Cash Flow (FCF) yield of approximately -51.76%. Compared to its 3-year average FCF yield of -117.14%, the current FCF yield is approximately -55.81% lower. Relative to its 5-year average FCF yield of -77.26% , the current FCF yield is about -33.00% lower.
P/B
Median3y
7.38
Median5y
5.50
FCF Yield
Median3y
-117.14
Median5y
-77.26
Competitors Valuation Multiple
AI Analysis for SGMO
The average P/S ratio for SGMO competitors is 20.52, providing a benchmark for relative valuation. Sangamo Therapeutics Inc Corp (SGMO.O) exhibits a P/S ratio of 1.41, which is -93.15% above the industry average. Given its robust revenue growth of -98.82%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SGMO
1Y
3Y
5Y
Market capitalization of SGMO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SGMO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SGMO currently overvalued or undervalued?
Sangamo Therapeutics Inc (SGMO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.41 is considered Undervalued compared with the five-year average of -4.15. The fair price of Sangamo Therapeutics Inc (SGMO) is between 1.88 to 4.29 according to relative valuation methord. Compared to the current price of 0.45 USD , Sangamo Therapeutics Inc is Undervalued By 76.02% .
What is Sangamo Therapeutics Inc (SGMO) fair value?
SGMO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sangamo Therapeutics Inc (SGMO) is between 1.88 to 4.29 according to relative valuation methord.
How does SGMO's valuation metrics compare to the industry average?
The average P/S ratio for SGMO's competitors is 20.52, providing a benchmark for relative valuation. Sangamo Therapeutics Inc Corp (SGMO) exhibits a P/S ratio of 1.41, which is -93.15% above the industry average. Given its robust revenue growth of -98.82%, this premium appears unsustainable.
What is the current P/B ratio for Sangamo Therapeutics Inc (SGMO) as of Jan 09 2026?
As of Jan 09 2026, Sangamo Therapeutics Inc (SGMO) has a P/B ratio of 22.62. This indicates that the market values SGMO at 22.62 times its book value.
What is the current FCF Yield for Sangamo Therapeutics Inc (SGMO) as of Jan 09 2026?
As of Jan 09 2026, Sangamo Therapeutics Inc (SGMO) has a FCF Yield of -51.76%. This means that for every dollar of Sangamo Therapeutics Inc’s market capitalization, the company generates -51.76 cents in free cash flow.
What is the current Forward P/E ratio for Sangamo Therapeutics Inc (SGMO) as of Jan 09 2026?
As of Jan 09 2026, Sangamo Therapeutics Inc (SGMO) has a Forward P/E ratio of -2.19. This means the market is willing to pay $-2.19 for every dollar of Sangamo Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sangamo Therapeutics Inc (SGMO) as of Jan 09 2026?
As of Jan 09 2026, Sangamo Therapeutics Inc (SGMO) has a Forward P/S ratio of 1.41. This means the market is valuing SGMO at $1.41 for every dollar of expected revenue over the next 12 months.